- Recommendation ID
- Adding a newer anti-anginal drug to a calcium channel blocker:- What is the clinical and cost effectiveness of adding a newer anti-anginal drug (nicorandil, ivabradine or ranolazine) to a calcium channel blocker for treating stable angina?
- Any explanatory notes
- Why this is important:- We do not know the long-term clinical and cost effectiveness of adding a
newer anti-anginal drug to a calcium channel blocker in people with stable angina. We propose a double-blind placebo-controlled randomised trial comparing the addition of a newer anti-anginal drug to a calcium channel blocker with a calcium channel blocker alone in people with stable angina
whose symptoms are not being controlled. Endpoints would include symptom severity, quality of life, long-term morbidity and mortality, and cost effectiveness. The results of the trial would influence clinical practice and inform future updates of key recommendations in this guideline.
Source guidance details
- Comes from guidance
- Stable angina: management
- Date issued
- July 2011
|Is this a recommendation for the use of a technology only in the context of research?||No|
|Is it a recommendation that suggests collection of data or the establishment of a register?||No|